{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:34:36Z","timestamp":1778272476546,"version":"3.51.4"},"reference-count":41,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2003,8,28]],"date-time":"2003-08-28T00:00:00Z","timestamp":1062028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Artificial Organs"],"published-print":{"date-parts":[[2003,9]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> Recognition of the role of the extracellular calcium sensing receptor (CaR) in mineral metabolism has greatly improved our understanding of calcium homeostasis. The activation of this receptor by small changes in extracellular ionized calcium (<jats:sub>ec<\/jats:sub>(Ca<jats:sup>2+<\/jats:sup>)) regulates PTH, calcitonin secretion, urinary calcium excretion, and ultimately, bone turnover. The cloning of this CaR and the discovery of mutations making the receptor less or more sensitive to calcium allowed a better understanding of several hereditary disorders characterized either by hyperparathyroidism or hypoparathyroidism. This CaR became an ideal target for the development of compounds, the calcimimetics, able to amplify the sensitivity of the CaR to <jats:sub>ec<\/jats:sub>(Ca<jats:sup>2+<\/jats:sup>) suppressing PTH levels with a resultant fall in blood Ca<jats:sup>2+<\/jats:sup>. The first clinical studies with first\u2010generation calcimimetic agents have demonstrated their efficacy lowering plasma intact PTH concentration in uremic patients with secondary hyperparathyroidism. However, the low bioavailability of these first calcimimetics predicts a difficult clinical utilization. The second\u2010generation calcimimetic AMG\u2010073, with a better pharmacokinetic profile, appears to be effective and safe for the treatment of secondary hyperparathyroidism, producing suppression of PTH levels with a simultaneous reduction in serum phosphorus levels and the calcium X phosphorus product. The advantage of controlling PTH secretion without the complications related to hypercalcemia, hyperphosphatemia, and increased calcium X phosphorus product is very promising.<\/jats:p>","DOI":"10.1046\/j.1525-1594.2003.07262.x","type":"journal-article","created":{"date-parts":[[2003,8,28]],"date-time":"2003-08-28T10:25:53Z","timestamp":1062066353000},"page":"759-764","source":"Crossref","is-referenced-by-count":9,"title":["Use of Calcimimetics in Uremic Patients with Secondary Hyperparathyroidism: Review"],"prefix":"10.1111","volume":"27","author":[{"given":"Pablo","family":"Ure\u00f1a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,8,28]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/13.11.2755"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.323"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0221-8747(81)90005-9"},{"key":"e_1_2_11_5_2","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1681\/ASN.V341008","article-title":"Short and long\u2010term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients.","volume":"3","author":"Gagn\u00e9 ER","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_6_2","first-page":"573A","article-title":"Single doses of the calcimimetic AMG\u2010073 reduce parathyroid hormone levels in a dose\u2010dependent manner in hemodialysis patients with secondary hyperparathyroidism.","volume":"11","author":"Coburn J","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.33.21267"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.suppl_11.20"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/366575a0"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117890"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:10:2:97"},{"key":"e_1_2_11_12_2","first-page":"115","article-title":"Structure and function of the extracellular calcium\u2010sensing receptor (Review).","volume":"4","author":"Bai M.","year":"1999","journal-title":"Int J Mol Med"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.36.23605"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)76148-1"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1999.14.6.878"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.11.3107"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.41"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.4.1598"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00986.x"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.12.2206"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000024439.38838.03"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100775200"},{"key":"e_1_2_11_23_2","first-page":"1083","article-title":"Allosteric activation of the Ca2+ receptor in Xenopus laevis oocytes by NPS 467 or NPS 568.","volume":"53","author":"Hammerland L","year":"1998","journal-title":"Mol Pharmacol"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M202113200"},{"key":"e_1_2_11_25_2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.V115903","article-title":"Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats.","volume":"11","author":"Chin J","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(99)00263-X"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00735.x"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119851"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00782.x"},{"key":"e_1_2_11_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70120-7"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711203372104"},{"key":"e_1_2_11_32_2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1210\/jcem.83.4.4726","article-title":"Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent.","volume":"83","author":"Collins MT","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_11_33_2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.","volume":"13","author":"Goodman WG","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_34_2","first-page":"248","article-title":"The calcimimetic AMG\u2010073 reduces parathyroid hormone (PTH), phosphorus, and calcium \u00d7 phosphorus product in secondary hyperparathyroidism.","volume":"63","author":"Lindberg J","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_35_2","first-page":"771A","article-title":"The calcimimetic AMG 073 reduces PTH and Ca x P in patients with secondary hyperparathyroidism (SHPT).","volume":"12","author":"Quarles LD","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_36_2","first-page":"572A","article-title":"The calcimimetic AMG\u2010073: A potential novel therapy for secondary hyperparathyroidism (SHPT).","volume":"13","author":"Block G","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_37_2","first-page":"572A","article-title":"Two\u2010year treatment with the calcimimetic AMG\u2010073 in hemodialysis patients with secondary hyperparathyroidism (SHPT).","volume":"13","author":"Moe S","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_38_2","first-page":"572A","article-title":"The effects of one\u2010year treatment with the calcimimetic AMG\u2010073 on bone health in ESRD patients with secondary hyperparathyroidism (SHPT).","volume":"13","author":"Quarles L","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_39_2","first-page":"633A","article-title":"Self\u2010reported cognitive functioning in hemodialysis patients with secondary HPT: The effect of the calcimimetic AMG\u2010073.","volume":"13","author":"Chertow G","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_40_2","first-page":"702A","article-title":"The SF\u201036 scales and the KDQOL cognitive functioning scale are reliable, valid and responsive in hemodialysis patients with secondary hyperparathyroidism.","volume":"13","author":"Lindberg J","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_41_2","first-page":"151","article-title":"Glandes parathyro\u00efdes, r\u00e9cepteur du calcium et calcimim\u00e9tiques.","volume":"23","author":"Ure\u00f1a P.","year":"2002","journal-title":"N\u00e9phrologie"},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.52.1.203"}],"container-title":["Artificial Organs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1525-1594.2003.07262.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1525-1594.2003.07262.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T10:04:55Z","timestamp":1697191495000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1525-1594.2003.07262.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,28]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["10.1046\/j.1525-1594.2003.07262.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1525-1594.2003.07262.x","archive":["Portico"],"relation":{},"ISSN":["0160-564X","1525-1594"],"issn-type":[{"value":"0160-564X","type":"print"},{"value":"1525-1594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,28]]}}}